Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers
Symptom-driven Combination Inhaled Corticosteroids and Long-acting Beta Agonist Therapy for Patients With Asthma Who Are Identified as Non-adherent to Daily Maintenance Inhalers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Abigail Zulich
- Phone Number: 314-747-3063
- Email: azulich@wustl.edu
Study Contact Backup
- Name: Tammy Quinones
- Phone Number: 314-747-3063
- Email: tkoch@wustl.edu
Study Locations
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Washington University in St. Louis School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to understand and provide informed consent.
- Age 12-75 at the time of study enrollment.
- Provider diagnosed mild or moderate persistent asthma and prescribed maintenance ICS treatment and as needed SABA for at least 6 months prior to enrollment.
- Suboptimal adherence to prescribed maintenance ICS therapy defined as missing at least expected 2 ICS refills in the prior 6 months based on examination of pharmacy records or a Medication Adherence Report Scale for Asthma (MARS-A) score <4.5.
- An Asthma Control Test (ACT) score at enrollment greater than or equal to 12 but less than or equal to 20 indicating partially controlled or moderately uncontrolled asthma. Adolescents age 12-17 with an ACT score 12-25 will be considered eligible.
- iPhone or Android smartphone with an active data plan and willingness to use the Adherium device.
Exclusion Criteria:
- Relevant comorbid pulmonary diseases including, but not limited to a diagnosis of chronic obstructive pulmonary disease (COPD), cystic fibrosis, or alpha 1 anti-trypsin deficiency.
- Current use of a biologic medication or investigational treatment for asthma.
- History of asthma requiring ICU admission in the last year.
- Unwillingness to use or pay for an inhaler that is compatible with the Adherium sensor (fluticasone propionate or budesonide/formoterol). Of note, fluticasone and budesonide/formoterol are formulary tier 1-2 for Missouri Medicaid and most commercial insurances and are believed to be equally or less expensive as alternative inhalers for most patients.
- Any clinically significant abnormalities on physical exam, laboratory testing, or baseline diagnostic testing that the study team believes will make the study unsafe.
- Patients who do not complete at least 70% of the twice-daily texts during the two weeks after screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: As needed inhaled corticosteroid and long-acting beta-agonist
Symptom-driven ICS/LABA treatment strategy
|
In this study, we propose a pragmatic, pilot, open-label trial where we are comparing adherence to different inhaler regimens.
Patients who were previously sub-optimally adherent to maintenance ICS inhalers will either continue receiving maintenance ICS inhalers and symptom-driven SABA inhalers or symptom-driven ICS/LABA inhalers only.
|
|
No Intervention: Standard therapy: maintenance inhaled corticosteroid and as needed short-acting beta-agonist
Continue maintenance ICS and SABA therapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adherence to inhaler strategy delineated using an electronic inhaler sensor
Time Frame: 24 weeks
|
The primary outcome will be adherence with an inhaler management strategy delineated using the Adherium inhaler sensor and smartphone application as compared between groups.
Adherence to the treatment strategy for the maintenance ICS inhaler group will be calculated as the proportion of maintenance ICS actuations per prescription recommendation.
Adherence for the symptom-based ICS treatment strategy will be calculated as the proportion of ICS/LABA actuations per recommendation based on self-report of symptoms (definition: ICS/LABA inhaler actuation during a day or night period divided by a period wherein a patient identified symptoms as >1 on REDCap-delivered smartphone questionnaire).
|
24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of asthma exacerbations
Time Frame: 24 weeks
|
Frequency of study-defined asthma exacerbations between groups (adjusted for time on treatment).
Asthma exacerbations will be defined as an urgent medical visit for asthma symptoms, prescription of oral corticosteroids for asthma symptoms, or high use of a rescue inhaler (>16 actuations of SABA or >8 actuations of ICS/LABA within 24 hours on two consecutive days as assessed via the Adherium device).
|
24 weeks
|
|
Time to asthma exacerbation
Time Frame: 24 weeks
|
Time to first exacerbation between groups.
Asthma exacerbations will be defined as an urgent medical visit for asthma symptoms, prescription of oral corticosteroids for asthma symptoms, or high use of a rescue inhaler (>16 actuations of SABA or >8 actuations of ICS/LABA within 24 hours on two consecutive days as assessed via the Adherium device).
|
24 weeks
|
|
ICS exposure
Time Frame: 24 weeks
|
Converted cumulative dose of ICS between groups.
|
24 weeks
|
|
Adverse and serious adverse events
Time Frame: 24 weeks
|
Occurrence of any severe and non-severe adverse events between groups.
|
24 weeks
|
|
Change in Asthma Control Questionnaire (ACQ)
Time Frame: 24 weeks
|
Change in Asthma Control Questionnaire (ACQ) from baseline to the final study visit.
|
24 weeks
|
|
Change in asthma control test (ACT)
Time Frame: 24 weeks
|
Change in Asthma Control Test (ACT) from baseline to the final study visit.
|
24 weeks
|
|
Change in Asthma Quality of Life Questionnaire (AQLQ)
Time Frame: 24 weeks
|
Change in Asthma Quality of Life Questionnaire (AQLQ) from baseline to the final study visit.
|
24 weeks
|
|
Change in Medication Adherence Reporting Scale for Asthma (MARS-A) questionnaire
Time Frame: 24 weeks
|
Change in Medication Adherence Reporting Scale for Asthma (MARS-A) questionnaire from baseline to the final study visit.
|
24 weeks
|
|
Change in IQVIA Treatment Satisfaction Questionnaire for Medication (TSQM)
Time Frame: 24 weeks
|
Change in IQVIA Treatment Satisfaction Questionnaire for Medication (TSQM) from baseline to the final study visit.
|
24 weeks
|
|
Change in The Knowledge, Attitude, and Self-Efficacy Asthma Questionnaire (KASEAQ)
Time Frame: 24 weeks
|
Change in The Knowledge, Attitude, and Self-Efficacy Asthma Questionnaire (KASEAQ) from baseline to the final study visit.
|
24 weeks
|
|
Change in Feeling of Satisfaction with Inhaler (FSI-10) questionnaire
Time Frame: 24 weeks
|
Change in Feeling of Satisfaction with Inhaler (FSI-10) questionnaire from baseline to the final study visit.
|
24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: James G Krings, MD MSc, Washington University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity, Immediate
- Hypersensitivity
- Behavior
- Treatment Adherence and Compliance
- Health Behavior
- Patient Compliance
- Patient Acceptance of Health Care
- Asthma
- Medication Adherence
- Organic Chemicals
- Amines
- Alcohols
- Amino Alcohols
- Ethanolamines
- Formoterol Fumarate
Other Study ID Numbers
Other Study ID Numbers
- 202108173
- UL1TR002345 (U.S. NIH Grant/Contract)
- KL2TR002346 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.